1. Home
  2. UWMC vs CGEM Comparison

UWMC vs CGEM Comparison

Compare UWMC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UWMC
  • CGEM
  • Stock Information
  • Founded
  • UWMC 1986
  • CGEM 2016
  • Country
  • UWMC United States
  • CGEM United States
  • Employees
  • UWMC N/A
  • CGEM N/A
  • Industry
  • UWMC Finance: Consumer Services
  • CGEM Biotechnology: Pharmaceutical Preparations
  • Sector
  • UWMC Finance
  • CGEM Health Care
  • Exchange
  • UWMC Nasdaq
  • CGEM Nasdaq
  • Market Cap
  • UWMC 971.2M
  • CGEM 730.2M
  • IPO Year
  • UWMC N/A
  • CGEM 2021
  • Fundamental
  • Price
  • UWMC $5.65
  • CGEM $12.39
  • Analyst Decision
  • UWMC Hold
  • CGEM Strong Buy
  • Analyst Count
  • UWMC 8
  • CGEM 7
  • Target Price
  • UWMC $7.41
  • CGEM $31.67
  • AVG Volume (30 Days)
  • UWMC 2.9M
  • CGEM 546.1K
  • Earning Date
  • UWMC 02-26-2025
  • CGEM 11-07-2024
  • Dividend Yield
  • UWMC 7.15%
  • CGEM N/A
  • EPS Growth
  • UWMC N/A
  • CGEM N/A
  • EPS
  • UWMC N/A
  • CGEM N/A
  • Revenue
  • UWMC $2,727,467,000.00
  • CGEM N/A
  • Revenue This Year
  • UWMC $2.19
  • CGEM N/A
  • Revenue Next Year
  • UWMC $26.43
  • CGEM N/A
  • P/E Ratio
  • UWMC N/A
  • CGEM N/A
  • Revenue Growth
  • UWMC 29.95
  • CGEM N/A
  • 52 Week Low
  • UWMC $5.44
  • CGEM $10.00
  • 52 Week High
  • UWMC $9.74
  • CGEM $30.19
  • Technical
  • Relative Strength Index (RSI)
  • UWMC 38.07
  • CGEM 47.96
  • Support Level
  • UWMC $5.59
  • CGEM $11.75
  • Resistance Level
  • UWMC $5.95
  • CGEM $12.95
  • Average True Range (ATR)
  • UWMC 0.26
  • CGEM 0.76
  • MACD
  • UWMC -0.00
  • CGEM 0.19
  • Stochastic Oscillator
  • UWMC 20.19
  • CGEM 77.69

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Share on Social Networks: